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7RESEARCH ARTICLE Open AccessMutations upstream of fabI in triclosan resistant
Staphylococcus aureus strains are associated with
elevated fabI gene expression
Denis Grandgirard1†, Leonardo Furi2†, Maria Laura Ciusa2, Lucilla Baldassarri3, Daniel R Knight4,8, Ian Morrissey4,9,
Carlo R Largiadèr5, Stephen L Leib1,6 and Marco R Oggioni2,7*Abstract
Background: The enoyl-acyl carrier protein (ACP) reductase enzyme (FabI) is the target for a series of antimicrobial
agents including novel compounds in clinical trial and the biocide triclosan. Mutations in fabI and heterodiploidy
for fabI have been shown to confer resistance in S. aureus strains in a previous study. Here we further determined
the fabI upstream sequence of a selection of these strains and the gene expression levels in strains with promoter
region mutations.
Results: Mutations in the fabI promoter were found in 18% of triclosan resistant clinical isolates, regardless the
previously identified molecular mechanism conferring resistance. Although not significant, a higher rate of
promoter mutations were found in strains without previously described mechanisms of resistance. Some of the
mutations identified in the clinical isolates were also detected in a series of laboratory mutants. Microarray analysis
of selected laboratory mutants with fabI promoter region mutations, grown in the absence of triclosan, revealed
increased fabI expression in three out of four tested strains. In two of these strains, only few genes other than fabI
were upregulated. Consistently with these data, whole genome sequencing of in vitro selected mutants identified
only few mutations except the upstream and coding regions of fabI, with the promoter mutation as the most
probable cause of fabI overexpression. Importantly the gene expression profiling of clinical isolates containing
similar mutations in the fabI promoter also showed, when compared to unrelated non-mutated isolates, a significant
up-regulation of fabI.
Conclusions: In conclusion, we have demonstrated the presence of C34T, T109G, and A101C mutations in the fabI
promoter region of strains with fabI up-regulation, both in clinical isolates and/or laboratory mutants. These data
provide further observations linking mutations upstream fabI with up-regulated expression of the fabI gene.
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Post-genomic research in the past years narrowed down
significantly the number of pathway proposed to be suit-
able as targets for antimicrobial treatment. Based on this,
the type II fatty acid biosynthesis pathway shows much
promise [1]. One frequently targeted enzyme in this path-
way is the enoyl-acyl carrier protein (ACP) reductase en-
zyme (FabI) as witnessed by the multiple Staphylococcus* Correspondence: mro5@leicester.ac.uk
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unless otherwise stated.aureus FabI inhibitors in clinical trial [2-5]. This is further
underlined by the fact that FabI is the target of the first
line anti-tuberculosis drug isoniazid, diazaborines and the
biocide triclosan [1,6]. The latter is a synthetic, non-ionic,
chlorinated bis-phenol and is present in many health care
products for both hospital and consumer use [7]. It pos-
sesses broad spectrum antimicrobial activity against many
Gram-positive and Gram-negative bacteria, some fungi
[8], and protozoa including Plasmodium falciparum and
Toxoplasma gondii [8]. Triclosan, unlike other biocides, at
low concentrations has a single intracellular target by
binding to the active site of the FabI. It forms a stablentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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losterically blocking the active site, and therefore prevents
bacteria from synthesising fatty acids, which are necessary
for building cell membranes and for division [9].
Several studies have demonstrated that bacteria have
both natural and acquired mechanisms of resistance to
triclosan. Natural resistance is present to varying
degrees in bacterial species, which harbour alternatives
to fabI, (fabK, fabL or fabV) [10-13]. In addition, bio-
degradation has been found to occur in different
environmental species [14]. The primary mechanism of
acquired resistance is due to mutations within the
coding region of fabI, which decrease affinity of the
enzyme to triclosan [9,15-19]. Alternatively, active efflux
of triclosan has been described in several Gram-
negative species, and is mediated by the resistance-
nodulation-division (RND) family of pumps [20]. It has
been shown that triclosan can activate the transcrip-
tional regulator SmeT of the SmeDEF efflux transporter
in Stenotrophomonas maltophilia [21].
In addition to target modification and efflux, also
titration of the target enzymes has been found to confer
resistance. Recent findings have shown the presence of
an additional copy of fabI, horizontally transferred from
S. haemolyticus, in the genome of many S. aureus
isolates with reduced susceptibility to triclosan [22].
Fatty acid biosynthesis is finely regulated in S. aureus by
a feed-forward system that globally controls the expres-
sion of genes involved in this metabolic pathway and
that is dependent on the malonyl-CoA intracellular
levels [23,24]. This metabolite was shown to bind to and
therefore to inhibit the activity of the transcriptional
repressor FapR [23]. FapR is a homodimeric repressor
highly conserved in Gram positive organisms that has
been characterized for its inhibitory function of the
expression of genes involved in the fatty acids and phos-
pholipids biosynthetic pathways [23,24]. Among others,
FapR was shown to directly interact with the promoter
of fabI and to physiologically regulate its expression
[24]. In analogy to the isoniazide resistance conferring
mutation in Mycobacterium tuberculosis [6], increased
amount of the FabI enzyme has been described in triclo-
san resistant S. aureus strains [16], however no gene
expression data are available to sustain this finding. Fur-
thermore, increased levels of fabI expression have been
observed in in vitro adapted S. aureus derivatives, with a
possible role of promoter mutations in some of these
strains [25]. Therefore, the aim of this study was to
further characterize mechanisms of resistance in a co-
hort of previously described S. aureus clinical isolates
and in vitro selected mutants with reduced susceptibility
to triclosan by sequencing the putative promoter region
of fabI and by evaluating the levels of gene expression
using microarray analysis.Results
Promoter sequence analysis
Seven out of thirty-eight (18%) triclosan resistant S. aureus
clinical isolates sequenced were found to have polymor-
phisms in the fabI upstream region (Additional file 1:
Supplementary data S1). Sequence data showed that the
C34T substitution was the most frequent SNP (5 strains),
while the SNPs A101C and T109G were found only once
(Table 1, Figure 1). The latter SNP was found in clinical
isolate QBR-102278-1052 where the insertion of an IS256
element upstream the fabI gene created an eight bp dupli-
cation (AAAAAGTC), which generated the T109G poly-
morphism (Table 1; Figure 1). No mutations were found
in the nineteen triclosan susceptible isolates (Additional
file 1: Supplementary data S1). FabI promoter mutations
were found in 3 out of 9 strains of the group of isolates
without any known triclosan resistance marker, 2/15 in
the strains with sa-fabI mutations and 2/14 in the strains
carrying the sh-fabI gene. When we previously analysed
the sa-fabI locus in the twenty-three in vitro selected tri-
closan mutant strains, we found that all (23/23) had a
mutated sa-fabI gene [22]. Now we found that about
half (13/23) of these had an additional sa-fabI promoter
mutation (Table 1; Figure 1; Additional file 1: Supplementary
data S1). The majority of the mutations in the sa-fabI pro-
moter reflected those found in clinical isolates, except
for the A7G and A72G SNPs and the A101 deletion
(Table 1; Figure 1). Similar to the clinical isolates, the
C34T mutation was the most represented polymorphism
(Table 1; Figure 1). In order to identify other genetic deter-
minants possibly involved in triclosan reduced susceptibil-
ity, seven mutants were further analysed by whole genome
sequencing. These data revealed that only mutations in
the fabI locus were shared by all strains. MO052 was the
only strain analysed by microarray containing additional
SNPs, but no obvious associations between these and
changes in the transcriptome could be made (Table 2 and
Additional file 2: supplementary data S2).
Gene expression analysis
Laboratory mutants
Transcriptomic differences between triclosan susceptible
wild type strains and their resistant isogenic mutants
were analysed by microarrays. Four pairs with different
mutations in the promoter regions were compared
(Table 3 and Table 4). Strains with the following promoter
mutations were analysed: A7G in MO036 and A72G in
MO034 were mutations documented only in laboratory
strains, but not in clinical isolates. C34T in MO035 was
the most frequently observed mutation in both laboratory
strains and clinical isolates. Finally, we also analysed
T109G, the second most frequent mutation in the labora-
tory strains, which was also identified in a clinical isolate
(Table 3, Figure 1). fabI was up-regulated in three of the
Table 1 Genotypes and phenotypes of in vitro mutants and clinical isolates with fabI promoter mutations
Strain Background sa-fabI promoter** sa-fabI‡ sh-fabI‡ MIC*‡ MBC*‡ Comment
RN4220 - wt wt - 1 2
MW2 - wt wt - 0.12 0.12
ATCC6538 - wt wt - 0.12 0.25
MO036 RN4220 A7G mutated - 4 8
MO035 RN4220 C34T mutated - 8 8
MO047 RN4220 C34T mutated - 4 8
MO049 RN4220 C34T mutated - 4 8
MO076 MW2 C34T mutated - 4 8
CR002 ATCC6538 C34T mutated - 4 8
MO034 RN4220 A72G mutated - 8 8
MO077 MW2 A101- mutated - 4 32 1 bp deletion
d7 ATCC6538 A101- mutated - 2 8 1 bp deletion
MO051 ATCC6538 T109G mutated - 4 8
MO052 ATCC6538 T109G mutated - 8 16
MO053 ATCC6538 T109G mutated - 4 8
MO055 ATCC6538 T109G mutated - 4 8
QBR-102278-1097 - C34T mutated - 0.25 32
QBR-102278-1889 - C34T wt - 0.5 16
QBR-102278-1969 - C34T wt - 0.25 32
QBR-102278-2095 - C34T wt - 0.25 32
QBR-102278-2546 - C34T mutated + 1 64
QBR-102278-2363 - A101C wt + 16 32
QBR-102278-1052 - T109G wt + 0.5 64 IS256 insertion
*MIC and MBC to triclosan are expressed as mg/L. **Polymorphic sites are indicated counting backwards from the sa-fabI start site of S. aureus Mu50 (GenBank ID:
BA000017; position 1060308). Strains analysed by microarray are indicated in bold. ‡With the exception of strain QBR-102278-2095, these data have been previously
reported [22].
Figure 1 Mapping of mutations in the intergenic region upstream sa-fabI. The sa-fabI upstream region from the S. aureus Mu50 genome
(GenBank ID: BA000017) is reported. Nucleotides in which mutations have been identified are marked in bold. The positions of the mutations are
reported with respect to the first nucleotide preceding the start codon of sa-fabI and numbered backwards. The nucleotide substitution is
described above the mutation position together with the number of clinical isolates (italicised number) and mutant strains carrying that particular
mutation. ATCC6538 sa-fabI upstream region sequence is identical to Mu50, while the naturally occurring polymorphisms identified in the wt
strains RN4220 (A92T; GenBank ID: AFGU01000045), ATCC25923 (A213T, A188C; GenBank ID: CP009361), and MW2 (T224A; GenBank ID: BA000033)
with respect to the Mu50 sequence are not reported as they do not affect triclosan susceptibility. The putative −35 and −10 consensus sequences,
identified by BPROM, are underlined. The consensus of the transcriptional repressor FapR recognition sequence is reported as mapped in RegPrecise
(underlined) [26] or as previously reported by alignment with the experimentally determined one in the fapR upstream region (dotted underlined)
[23,24]. The transcriptional start site (+1TSS) as identified by RNAseq [50] and the ribosomal binding site (SD) are also reported.
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Table 2 Polymorphic changes in the genome of in vitro mutant strains
Ref. genome
positions*
Annotation RN4220 derived ATCC6538 derived Mu50 derived
NCTC8325 Mu50 MO034 MO035 MO036 d2** d7 MO052 MO079**
120767 Capsular polysaccharide synthesis
enzyme Cap5B
A 592 T – Met 198 Leu
208900 Pyruvate formate-lyase 1-activating
enzyme
G 721 T - Val
241 Phe
226813 Flavohemoprotein -TA 953 deletion leading to
transcription premature truncation
784247 Protein traslocase subunit SecG T 22 A – Leu 8 Ile
919922 fabI upstream region** T 109 G
919929 fabI upstream region A 101 deletion
919959 fabI upstream region A 72 G
919997 fabI upstream region C 34 T
920024 fabI upstream region A 7 G
920098 fabI coding region G 68 C – Gly
23 Ala
920331 fabI coding region G 301 T – Asp
101 Tyr
G 301 T – Asp
101 Tyr
920469 fabI coding region T 439 C – Tyr 147 His
920641 fabI coding region T 611 G – Phe
204 Cys
T 611 G – Phe
204 Cys
1060928 fabI coding region T 611 A – Phe
204 Tyr
1139511 serine/threonine-protein kinase PrkC G 1309 A – Val 437 Ile
1231020 DNA mismatch repair protein MutL T 1709 A – Ile
569 Asn
1238213 MurD UDP-N-acetylmuramoyl-L-alanyl-
D-glutamate synthetase
T 338 G – Ile
113 Ser
1238872 MurD UDP-N-acetylmuramoyl-L-alanyl-
D-glutamate synthetase
C 997 G – Leu
333 Val
1588812 tRNA methylthiotransferase YqeV G 824 A – Ile 275 Thr
2335216 HTH-type transcriptional regulator SarV C 140 A – Val 47 Gly
2774594 Ica operon transcriptional regulator, IcaR -TCTTTTGTCA 417 deletion leading
to transcription premature truncation
*The nucleotide position refers to the genome of S. aureus NCTC8325 (accession NC_007795) or Mu50 (accession NC_002758). Polymorphic sites of fabI promoter region are indicated counting backwards from the
sa-fabI start site of S. aureus Mu50 (GenBank ID: BA000017; position 1060308). **Despite not having fabI promoter mutations the d2 and MO079 mutants have been included in the analysis to check for the presence
of mutations (not only in the fabI coding sequence) playing a possible role in triclosan reduced susceptibility.
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Table 3 Overview of the changes in gene expression in laboratory mutants and clinical isolates
Comparison strains Promoter mutation Up-regulated genes Down-regulated genes Fold increase fabI expression
MO034 vs RN4220 A72G 154 125 4.97
MO035 vs RN4220 C34T 7 - 3.92
MO036 vs RN4220 A7G 2 - -
MO052 vs ATCC6538 T109G 3 20 3.47
QBR-102278-1889 vs ATCC25923 C34T 76 18 4.86
QBR-102278-1969 vs ATCC25923 C34T 78 36 6.44
QBR-102278-2363 vs ATCC25923 A101C 122 28 4.26
QBR-102278-1052 vs ATCC25923 T109G 198 8 47.6
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pression between 3.47 and 4.97 (Table 3 and Table 4). The
fabI gene was the highest up-regulated in both MO035
and MO052 (Additional file 2: Supplementary data S2).
MO034 was characterized by a higher number of up- and
down-regulated genes (Additional file 2: Supplementary
data S2) with fabI being the third highest regulated probe.
In contrast the strain MO036, carrying the A7G mutation,
was not found to have an up-regulated fabI expression. In
this strain, only two genes, not previously described to be
involved in the development of triclosan resistance, were
slightly up-regulated (Additional file 2: Supplementary
data S2). No further significant association were observedTable 4 fabI/gyrA ratio of laboratory and clinical strains
Strains Log2 fabI/gyrA ratio* t test vspar
Laboratory strains
RN4220 (n = 6) 1.69
MO034 (n = 5) 2.49 0.04
MO035 (n = 5) 3.37 0.0002
MO036 (n = 3) 1.41 ns
MU50 (n = 5) −0.28
ATCC6538 (n = 4) 0.14
MO052 (n = 4) 2.14 0.0002
ATCC25923 (n = 4) −0.51
Clinical strains
QBR-102278-1052 (n = 4) 4.22
QBR-102278-1889 (n = 4) 1.25
QBR-102278-1969 (n = 4) 1.56
QBR-102278-2363 (n = 4) 1.16
QBR-102278-1016 (n = 3) 0.23
QBR-102278-1027 (n = 4) 0.13
QBR-102278-2628 (n = 5) 0.03
*Log2 ratio was independently determined for each chip using the data before stag
obtained from the eight probes for gyrA printed on the chip from the Log2 mean fa
of chips used by strains (n). Student’s unpaired t-test was performed by comparing
reference strains in the case of clinical isolates. ns = not significant.between polymorphisms retrieved with the whole genome
sequencing and up- and down-regulation of correspond-
ing genes in mutant strains.
Clinical isolates
A comparison between triclosan resistant clinical isolates
containing mutations in the fabI promoter and sensitive
prototypical strains was also performed. Four clinical
isolates with reduced triclosan susceptibility (Table 3)
were compared to the prototypical, triclosan susceptible
S. aureus strain ATCC25923 (MIC and MBC of 0.06 and
1 mg/L respectively). Two of these strains (QBR-102278-
1889 and QBR-102278-1969) had the same fabI promoterental strain t test vs ATCC 6538 t test vs ATCC25923
<0.0001 <0.0001
0.0026 0.0137
0.0002 0.0059
0.004 0.016
ns ns
ns ns
ns ns
e-wise quantile normalization, by subtracting the Log2 mean gyrA values
bI values from the two probes. Ratio was then further averaged for the number
the mutants to their parental strains in the case of laboratory strains, or to two
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strain (QBR-102278-1052) had the mutation T109G, also
found in MO052. Finally, one strain (QBR-102278-2363)
showed a mutation (A101C) in a region deleted in two
laboratory strains, which were however not tested by mi-
croarrays (Table 3, Figure 1). A higher number of up- or
down-regulated genes were found in these clinical isolates
than in laboratory strains, except MO034. This was ex-
pected, since the comparison could not be made between
isogenic strains. Furthermore, the genetic diversity of
these strains may be augmented by the presence of plas-
mids not present in ATCC25923. Nevertheless, in all clin-
ical strains, fabI was up-regulated, from 4.26 to 47.6 fold
(Table 3, Table 4, and Additional file 2: Supplementary
data S2). Also the Log2 fabI/gyrA ratios were found to be
significantly higher in the four clinical strains with de-
creased sensitivity to triclosan when compared to the two
reference strains ATCC6538 and ATCC25923 (Table 4).
This was in contrast to 3 triclosan susceptible strains
(QBR-102278-1016, QBR-102278-1027, and QBR-102278-
2628; described in Additional file 1: Supplementary data
S1), which showed ratios comparable to the reference
strains (Table 4). Quantitative real-time PCR confirmed a
statistically significant increase of comparable entity in the
expression of the fabI gene of clinical isolates when com-
pared to reference strains (using gyrA as housekeeping
control). The increase was for the fabI gene of QBR-
102278-1052, QBR-102278-1889, QBR-102278-1969, and
QBR-102278-2363 respectively 36.9, 9.0, 15.6, and 7.7 fold
compared to ATCC6538 and of 9.9, 2.4, 4.2, and 2.1 fold
when compared to ATCC25923. QBR-102278-1052, the
strain with the highest up-regulation of fabI and the high-
est MBC was also characterized by the presence of an
IS256 element upstream of the promoter. Other possible
mechanisms of triclosan resistance in these clinical strains
were evaluated by identifying the genes commonly up- or
down- regulated in the four clinical isolates. 37 genes were
found to be up-regulated in all 4 strains (Tables 5, 6 and
Additional file 3: Supplementary data S3). Furthermore,
6 genes were down-regulated. Apart from fabI, all genes
found to be up- or down- regulated were of chromosomal
origin, meaning that, at least in the four clinical isolates
tested in the present study, triclosan resistance is not
plasmid-mediated at the level of gene expression. Gene
ontology (GO) annotations were available for 29 genes
of all 43 differently regulated genes (Additional file 3:
Supplementary data S3). Genes involved in transport (8 genes)
or in membrane structure/metabolism (12 genes) were the
most represented. These intrinsic differences in bacterial
membrane properties could influence triclosan tolerance inde-
pendently from fabI, for example by altering triclosan traffick-
ing through the membrane. However, we did not find genes
coding for efflux pumps or known antibiotic/biocide resist-
ance genes to be up-regulated (Tables 5 and 6).Discussion
Several mechanisms inducing reduced triclosan suscepti-
bility have been described in both Gram-positive and
Gram-negative organisms [9-22]. Amongst them, muta-
tions in the coding regions of the fabI gene or an increase
in its expression level have been related to triclosan resist-
ance [9,15-19].
The analysis of the fabI upstream region in triclosan
resistant clinical isolates and in vitro selected mutant
strains revealed the presence of nucleotide changes with
respect to triclosan susceptible strains. Interestingly three
mutations (T109G, A101C, and A101-del) were found to
occur within the FapR DNA recognition sequence. These
mutations are likely to interfere with FapR binding, there-
fore reducing its inhibitory effect on fabI transcription.
More importantly, the thymine in the 109 position was
found to be highly conserved among the FapR DNA recog-
nition sequences [26], while the 101 adenine was previ-
ously showed to be specifically recognized and bound by
the Arg56B residue of FapR [23]. It is noteworthy that the
A72G mutation, present only in a laboratory mutant strain,
was found to occur between the predicted −35 and −10
promoter sequences. On the other hand no clear indica-
tion on the mode of action of the C34T mutation, located
7 bp downstream the transcription start site, could be
found. The high frequency of this mutation in clinical iso-
lates points to an important regulatory effect, which might
be hypothesised to be linked to post-transcriptional regu-
lation. A hypothesis strengthened by the high level of
sequence identity, including a complete match of the se-
quence preceding C34, between the staphylococcal fabI 5-
prime UTR to Enterococcus faecalis [27]. However further
studies will be required to determine the exact nature of
such regulatory events.
Our data indicate that mutations in the fabI upstream re-
gion were not always found to be associated to other previ-
ously described triclosan resistance mechanisms. Indeed,
fabI promoter mutated strains were found either alone or
associated to the presence of the sh-fabI gene or mutations
in the sa-fabI. In particular we found three triclosan resist-
ant clinical strains with mutations in the fabI promoter, but
not in the coding region. In two of these strains analysed by
microarray an up-regulation of the fabI gene was also ob-
served suggesting that these promoter mutations in fabI
may induce overexpression and participate in triclosan re-
sistance. Although having mutation in the promoter re-
gion, the strain MO036 didn’t display higher level of fabI
gene expression. The most plausible cause of triclosan re-
sistance in this strain is the observed mutation in the cod-
ing region of the gene. However, isaA, overexpressed in
MO036, could also be an additional strategy contributing
to triclosan resistance, since its involvement has been re-
cently mentioned for fusidic acid resistance, by altering
cell wall metabolism and therefore cell properties [28].
Table 5 Genes up-regulated in triclosan resistant S. aureus clinical isolates with respect to ATCC25923
QBR-102778
Genes -1889 -1969 -2363 -1052
cycA / putative D-serine/D-alanine/glycine transporter 2.5 3.2 4.7 6.5
dltD / putative lipoteichoic acid biosynthesis protein 2.9 2.3 2.3 8.9
fabI / enoyl-acyl-carrier-protein reductase (NADH) 4.8 6.4 4.3 47.6
fruA / PTS transport system, fructose-specific IIABCcomponent 5.3 4.9 11.1 11.1
gyrA / DNA gyrase subunit A 2.6 2.4 2.2 3.4
hlb / phage protein 3.2 2.6 4.9 10.5
isaB / hypothetical protein 2.8 2.4 2.5 5.4
mprF / putative membrane protein 4.5 2.2 6.8 8.3
murA1 / putative UDP-N-acetylglucosamine1-carboxyvinyltransferase 4.6 4.3 8.3 17.1
rho / transcription termination factor 2.2 2.2 3.3 7.4
rir1 / ribonucleoside-diphosphate reductase alphachain 2.4 2.1 2.4 4.0
SATW20_19350 / phage protein 6.0 5.9 10.6 17.9
SAV0240 / SATW20_02420 / flavohemoprotein 10.6 18.4 26.0 13.7
SAV0348 / SATW20_04160 / hypothetical protein 2.1 2.1 3.5 2.3
SAV0465 / SATW20_05330 / putative exported protein 7.0 3.8 7.7 13.7
SAV0663 / SATW20_07380 / conserved hypothetical protein 4.8 5.4 9.0 14.1
SAV0699 / SATW20_07740 / putative phosphofructokinase 2.5 2.6 4.7 3.9
SAV0944 / SATW20_09440 / thioesterase superfamily protein 3.6 2.6 8.9 2.0
SAV1356 / SATW20_13570 / sodium:alanine symporter family protein 2.1 2.3 2.9 4.3
SAV1573 / SATW20_15690 / putative exported protein 3.0 2.2 4.6 5.5
SAV1853 / SATW20_18470 / putative membrane protein 2.7 2.5 3.0 2.9
SAV1914 / SATW20_19090 / putative oxygenase 3.9 2.7 6.6 6.6
SAV1947 / hypothetical protein 22.4 6.3 28.3 9.3
SAV2032 / SATW20_20150 / membrane anchored protein 3.3 2.2 3.3 3.7
SAV2184 / SATW20_23220 / putative membrane protein 4.8 4.1 7.2 6.0
SAV2253 / SATW20_23870 / xanthine/uracil permease family protein 6.2 3.4 3.8 3.7
SAV2253 / SATW20_23870 / xanthine/uracil permeases family protein 4.3 2.2 2.4 3.0
SAV2335 / SATW20_24670 / putative membrane protein 2.5 2.3 3.8 2.6
SAV2368 / SATW20_25000 / hypothetical protein 5.1 3.2 6.6 6.7
SAV2368 / SATW20_25000 / putative lipoprotein 9.8 6.6 16.1 10.0
SAV2383 / SATW20_25130 / putative exported protein 3.0 3.3 4.0 7.4
SAV2403 / SATW20_25330 / putative nitrite transporter 3.5 2.4 2.8 6.1
SAV2404 / SATW20_25340 / putative membrane protein 6.7 4.9 6.2 3.3
SAV2412 / SATW20_25420 / ABC transporter ATP-binding protein 10.1 8.5 16.3 25.5
SAV2413 / SATW20_25430 / ABC transporter permease 6.2 4.9 9.6 18.4
SAV2413 / SATW20_25430 / transport system membrane protein 3.9 3.4 4.7 8.0
SAV2414 / SATW20_25440 / extracellular solute-binding lipoprotein 2.4 2.2 3.1 5.0
scn / staphylococcal complement inhibitor SCIN 64.7 63.5 47.7 85.1
trap / signal transduction protein TRAP 10.6 9.5 16.7 21.7
xpt / putative xanthine phosphoribosyltransferase 7.8 6.5 12.5 12.9
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Table 6 Genes down-regulated in triclosan resistant S. aureus clinical isolates with respect to ATCC25923
QBR-102778
Genes -1889 -1969 -2363 -1052
fda / fructose-bisphosphate aldolase class I 0.03 0.02 0.03 0.04
SATW20_01020 / putative hydratase 0.17 0.15 0.29 0.30
SATW20_28340 / putative N-acetyltransferase 0.11 0.07 0.06 0.03
SAV0801 / hypothetical protein 0.17 0.16 0.15 0.13
SAV2515 / SATW20_26360 / transmembrane protein smpB 0.38 0.46 0.24 0.38
SAV2643 / SATW20_27810 / putative membrane protein 0.45 0.38 0.35 0.31
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coding region of fabI varied between mutant strains and
clinical isolates [22]. In contrast, there was good overlap
between in vitro selected fabI promoter mutations and
those of clinical strains in the present study (Figure 1).
On the other hand, phenotypic differences were evident
between mutants and clinical isolates carrying fabI pro-
moter mutations (Table 1). Indeed mutant strains showed
higher MICs values and lower MBCs values with respect
to clinical isolates. The higher MICs could be explained
by the technical constrain imposed by the mutant selec-
tion method [22] in which the active multiplying cells
need to be grown in presence of triclosan concentrations
sufficient to isolate resistant mutants from wt strains. On
the other hand in vivo concentrations of triclosan could
be lower, potentially transient and acting on bacteria with
greater generation times. These three aspects, not repro-
ducible in in vitro conditions, could have allowed for a dif-
ferent selection of triclosan resistant mutants in the
natural environment, including in the human host. Such
phenotypic differences were also reflected by the absence
of in vitro generated mutants showing the sole fabI up-
stream mutation (Table 1) confirming that our laboratory
mutant selection strategy couldn’t select triclosan resistant
strains without mutations in the fabI coding region, while
clinical isolates could evade triclosan bactericidal activity
by increasing the baseline expression of fabI through the
sole promoter mutations. However these divergences do
not indicate any reduction of fitness neither in the lab
strains nor the clinical isolates [29].
The technical constrain for selecting high MIC mu-
tants in vitro is due to the drug concentration used in
the screening of active multiplying cells. Probably in vivo
concentrations drug concentrations can be lower and
potentially transient and the bacterial generation time is
greater. These three aspects could allow a different se-
lection of mutants in vivo. Considering lower and transi-
ent drug concentration and possibly greater generation
time, it is possible that an increased baseline expression
may allow for out-titration of killing effect.
Microarray analysis confirmed that in all clinical strains
and the majority of lab mutants, promoter mutations wereassociated with an up-regulation of fabI transcription
(Tables 4, 5 and 6). Increased expression of fabI gene has
been described in triclosan-resistant S. aureus clinical iso-
lates [16], S. epidermidis mutants [30], laboratory mutants
of S. aureus [25], E. coli and Salmonella [31-33]. Promoter
mutation has never been linked to fabI over-expression
despite mutation in the fabI upstream region were previ-
ously identified in adapted S. aureus USA300 isolates [25].
Interestingly, the exposure of S. aureus [34], Salmonella
enterica or E. coli [35] to triclosan does not necessarily
lead to fabI up-regulation. One of our clinical strains
(strain QBR-102278-1052), distinguished itself by a very
high level (approx. 50 fold up-regulation) of fabI expres-
sion. It is of notice that quantitative real-time PCR con-
firmed the particularly high fabI expression of QBR-
102278-1052 isolate. In this clinical strain, the insertion
of an additional sh-fabI allele was also documented. Still,
the observed increase in signal on the microarray was
exclusively due to sa-fabI hybridization, since the two
oligonucleotide probes printed on the array were able to
discriminate sa-fabI from sh-fabI. Rather, we found an
IS256 insertion sequence element 114 bp upstream of and
in the same direction as the fabI gene in this strain. Mul-
tiple copies of IS256, not associated with any resistance
genes, have been found in the chromosome of S. aureus
[36], but also in many strains of Enterococcus faecalis
and E. faecium [37]. The formation of a potent hybrid
promoter containing IS256 could be a new additional mech-
anism leading to high level of fabI expression and de-
creased susceptibility to triclosan, which however remains
to be proven experimentally. This hypothesis would be
supported by the observation of a high level resistance to
methicillin and fluoroquinolones in S. aureus induced by
the insertion of IS256 upstream of the llm and norA genes
respectively [38,39]. A similar mechanism was also de-
scribed in Staphylococcus sciuri, in which methicillin re-
sistance was linked to the insertion of IS256 upstream of
the gene coding for a mecA homolog [40].
Our microarray analysis of triclosan-resistant clinical
isolates did not reveal any efflux-mediated resistance mechan-
ism, neither chromosomally-encoded, nor plasmid-mediated.
This is in agreement with previous studies showing that
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for S. aureus strains carrying plasmid-borne qac genes
coding for multidrug efflux pumps [41]. Similarly, over-
expression of the chromosomal norA multidrug trans-
porter gene did not lead to triclosan resistance [42].
Efflux-mediated resistance to triclosan is however not to
be excluded in Gram- positive bacteria. Indeed, it has been
recently shown that, out of 21 S. haemolyticus clinical
strains, an inhibition of efflux pump activity by carbonyl
cyanide-m-chlorophenylhydrazone (CCCP) significantly
decreased triclosan MIC in four strains [43] suggesting the
possible presence of a still unidentified efflux system with
triclosan as a substrate. Despite this fact, efflux-mediated
triclosan resistance to date still remains restricted to Gram-
negative species [20,21]. Other mechanisms inducing an
alteration of membrane metabolism, structure or traffick-
ing in S. aureus could not be excluded. This hypothesis
would be supported by the identification of several upreg-
ulated genes involved in such mechanisms in clinical
strains or isaA up-regulation in the laboratory mutant
MO036.
Apart from the fabI gene or efflux pumps, evidence for
other mechanisms of resistance to triclosan is scarce. Pro-
longed exposure of MRSA to triclosan-impregnated sili-
con elastomer resulted in the selection of small colony
variants resistant to triclosan, but the underlying mechan-
ism is still not understood and may be non-specific, in-
volving a reduction in energy generation and/or transport
and the down-regulation of functions such as cell wall
synthesis [44]. High-throughput methods (proteomics,
genomics) have been recently applied to laboratory strains
of S. typhimurium and E. coli grown in absence of triclo-
san in order to reveal inherent mechanisms of resistance
to triclosan based on changes in genes or proteins expres-
sion [32,33,45]. Apart from the consistent up-regulation
of fabI, relatively few new mechanisms were proposed.
It has been postulated that the increased expression of
dehydrogenases and oxidoreductases using NAD+ as a co-
factor, could bind and capture triclosan, reducing its ef-
fective intracellular concentration [32,45]. In the present
study, apart from fabI, only one putative flavohemo-
protein (SATW20_02420) containing identified bind-
ing sites for NAD or FAD was highly up-regulated in the
clinical strains. In most cases no complete operon was
found to be over-expressed in the triclosan resistant clin-
ical isolates. Exceptions are the co-transcribed fruA and
fruB genes and the three genes for an amino acid ABC
uptake system (SAV2412-4). This is in accordance with
previous data, which had shown that exposure of S. aureus
to triclosan leads to the de-regulation of branched
amino acid uptake and carbohydrate metabolism in-
cluding changes in expression of fruA, fruB and xprT
[34]. Albeit the partial overlap of data between our
characterisation of resistant isolates and the work ontriclosan toxicity, no clear metabolic correlation can be
drawn, which links triclosan and fatty acid metabolism
to the observed changes in gene expression. In that re-
spect, the current analyses of the six clinical isolates
devoid of any resistance markers could also provide
further insights, especially if fabI turns out not to be
overexpressed in these strains.
To our knowledge, this is the first extensive microarray
analysis comparing both in vitro generated mutants and
clinical isolates of S. aureus resistant to triclosan. The
comparison of the mutants and their parental strains en-
ables us to link genetic variations to phenotypic changes
more directly. For clinical strains, comparisons between
resistant strains and a prototypical strain do not allow
such direct conclusion and also relate to the choice of the
prototypical strain. These results were therefore con-
firmed by determining fabI/gyrA ratio. To definitely chal-
lenge the hypothesis that mutations in the promoter of
fabI lead to overexpression of the gene and consequently
to a reduced susceptibility, prospective genetic manipula-
tion would have been a more direct approach. Neverthe-
less, whole genome sequencing revealed in three out of
four laboratory mutant tested by microarray, that the only
mutation susceptible to explain change in fabI expression
was located in fabI promoter region. Furthermore, the fact
that the same fabI promoter mutations were found in all
clinical strains with overexpression of their fabI gene, in-
directly provide the evidence for the involvement of such
mutations in fabI up-regulation and possibly in triclosan
reduced susceptibility.
Conclusion
In conclusion, molecular changes in the promoter region
of fabI were identified together with fabI over-expression
and triclosan resistance. As such this overexpression of
fabI has the potential to determine cross-resistance to
novel compounds in clinical trial [2-5]. This adds to the
recently described mutations within fabI selected by the
novel compound AFN-1252 which confer cross-resistance
to triclosan [46]. It should be noted that in S. aureus fabI
up-regulation acts almost always in addition to the other
triggers of triclosan resistance, such as mutations in cod-
ing regions of the fabI gene or the insertion of an addition
allele derived from S. haemolyticus. Importantly, we could
not link triclosan resistance in staphylococci to the pres-
ence or over-expression of efflux systems, either of plas-
mid or chromosomal origin, a mechanism known to
contribute to resistance in Gram-negative organisms [47]
or to the resistance to any other antimicrobial drug [48].
In addition we have solid evidence of the fabI up-
regulation in four triclosan resistant clinical isolates for
which the intrinsic genetic diversity between clinical iso-
lates so far had eluded comparison of gene expression. In-
direct evidences support the relationship between fabI
Grandgirard et al. BMC Genomics  (2015) 16:345 Page 10 of 13overexpression and the presence of mutations mapped in
the FapR binding domain or other regions of the predicted
fabI promoter region. This hypothesis is further strength-
ened by the finding of the same mutations in fabI-overex-
pressing laboratory mutants, which, most importantly,
were shown to not carry any other mutation in their gen-
ome that could be associated to triclosan resistance. This
combined data in laboratory mutants and clinical isolates
opens new avenues to explore mechanisms of triclosan re-
sistance in S. aureus.
Methods
Bacterial strains
Sixty-five S. aureus strains with reduced susceptibility to
triclosan were previously selected from a collection of
1602 clinical isolates by performing standard MIC and
MBC assays [22,48,49]. Of these, fifteen strains with mu-
tations in the fabI coding sequence, fourteen with an
additional chromosomal sh-fabI allele (from S. haemoly-
ticus), and nine without any known triclosan “resistance”
marker were investigated in this work for fabI promoter
mutations (Additional file 1: Supplementary data S1). As
a control nineteen triclosan susceptible isolates were in-
cluded in the analyses (Additional file 1: Supplementary
data S1). In addition twenty-three independent mutants
(Additional file 1: Supplementary data S1), with re-
duced susceptibility to triclosan, were also analysed. These
strains have been previously selected by single-exposure
of ATCC6538, MW2, and Mu50 reference strains to
0.5 mg/L of triclosan in solid medium or by multiple
step-growth on liquid medium with increasing triclosan
concentrations (from 0.25 mg/L to 4 mg/L) as in the case
of the RN4220 laboratory strain [22].
No ethical approval was required to obtain the isolates
used in the study. No ethical approval was required to
use the clinical isolates in this study. Isolates were ob-
tained during routine microbiological investigations and
were not part of a clinical trial.
Molecular analysis
The upstream region of the fabI gene was amplified in
the fifty-seven clinical isolates and in the twenty-three
laboratory mutants. DNA was amplified using standard
PCR conditions and the following primers: 5′-ATCA
TCTTCGTGCGTATTATC-3′ and 5′-TTCAAGCTCT
TTACGGCTA-3′ (Eurofins MWG Operon, Germany).
PCR products were sequenced by the Sanger method
(Eurofins MWG Operon, Ebersberg, Germany). A selec-
tion of S. aureus fabI upstream sequences has been
deposited in GenBank (accession nos. KF583951- KF583970).
The putative −35 and −10 sequences have been predicted
using the BPROM tool (http://www.softberry.com/ber-
ry.phtml), while the FapR recognition sequence was
mapped by mean of the data available on the RegPrecisedatabase [26]. The transcriptional start site was identified
by direct visualisation of RNA-seq alignment data re-
trieved from the NCBI Sequence Read Archive (SRA,
http://www.ncbi.nlm.nih.gov/Traces/sra/). More pre-
cisely the illumina HiSeq data were previously generated
by sequencing of the RNA extracted from a S. aureus
Newman strain at the early log phase (SRA Experiment
ID: DRX011556, SRA Sample ID: DRS011392) [50].
Whole-genome sequencing was performed by the In-
stitute of Applied Genomics (University of Udine, Italy)
using an Illumina Genome Analyzer II platform (Illu-
mina, San Diego, California, USA) for the in vitro se-
lected mutants d2, d7, MO034, MO035, MO036, MO052,
MO079 and their isogenic wild type strain RN4220,
ATCC6538, and Mu50 (Table 2). Mutants to be sequenced
have been selected on the basis of their fabI promoter se-
quence in order to analyse one strain for each one of the
previously identified mutations. Strains d2 and MO079
have been also included in order to check for genetic
changes, other than sa-fabI mutations, possibly related to
their triclosan reduced susceptibility phenotypes. Se-
quences of both wt strains and mutant strains, were
aligned to the reference genome of S. aureus NCTC8325
(accession NC_007795), except for Mu50 and MO079 that
were aligned to the Mu50 genome (accession NC_002758),
using the Mosaik Assembler suite (The MarthLab, Boston
College, Massachusetts, USA). Single nucleotide poly-
morphisms (SNPs), insertions and deletions (INDELs)
were retrieved with VarScan software [51]. SNPs and
INDELs of the wt strains obtained from the alignment
with the GenBank reference genome were subtracted
from those found by aligning the mutant strain with
the reference.
Statistical analysis
Fisher’s exact test was applied to assess if the differences
in the number of clinical isolates with fabI promoter
mutations among the three groups of strains defined by
known triclosan resistance marker were statistically
significant.
Gene expression analysis
Array design and production
Probe design was performed by the CustomArray Design
Service. Probes of 35–40 bp length were selected based
on melting temperature (Tm), complexity, secondary
structure, GC-content, and specificity. A total of 12’000
capture probes were finally used. Furthermore, the array
also contained quality control spots, non-specific probes
derived from phages, plants, virus and bacteria, as well
as empty, oligonucleotide-free spots. The entire genomes
of Mu50 and TW20 were covered in the microarrays,
plus additional elements as listed in the Additional file 4:
Supplementary data S4. Arrays were synthesized on a
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and quality tested using the standard protocols provided
by the manufacturer.
Bacterial growth
S. aureus strains were grown overnight in 10 ml tryptic
soy broth (TSB) at 37°C at 80 rpm. The cultures were di-
luted 1:100 in pre-warmed TSB and grown to logarithmic
phase (OD570 = 0.6). 2 ml of each culture (1–5 × 10
8 col-
ony forming units) was harvested in 4 ml of RNAprotect®
reagent (Qiagen), incubated for 5 min at room temperature
and centrifuged for 10 min at 5000 × g. The pellet was
then processed directly for RNA extraction or stored
at −80°C for later processing.
RNA purification
Total RNA was extracted using RNeasy Mini Kit
(Qiagen), according to the manufacturer’s instructions,
using 50 U recombinant lysostaphin (Sigma) followed by
incubation for 5 minutes with 1 ml of hot Qiazol (Qiagen)
to lyse bacteria. Bacteria were further disrupted by vibration
with 50 mg of acid-washed glass beads (Sigma) using a
Mickle Vibratory Tissue Disintegrator (Mickle Laboratory
Engineering) at maximum speed. Contaminating DNA
was removed using DNA-free™ Kit (Applied Biosystems)
and RNA quality tested on an Agilent 2100 Bioanalyzer
(Agilent Technologies). RNA concentration and purity
were determined by Nanodrop® ND-1000 spectrophotom-
eter (Thermo Scientific). For each strain, at least 4 RNA
samples were prepared from independent cultures.
RNA labelling and fragmentation
Isolated, unamplified RNA was labelled with Cy5, using
ULS™ Labeling Kit for CombiMatrix arrays (Kreatech
Biotechnology), according to the manufacturer’s instructions.
RNA was finally fragmented with RNA Fragmentation
Reagents (Ambion®).
Array hybridization
12 K Customarrays were hybridized with 2 μg of la-
belled, fragmented RNA, according to information pro-
vided by the manufacturer (Customarray/Combimatrix
Incorporated). Microarrays were scanned using the Packard
ScanArray4000 array scanner and software (ScanArray, ver-
sion 3.1, Packard BioChip Technologies). All arrays were
scanned with incremental laser power from 15 to 100%.
Data were extracted with Microarray Imager software
(version 5.8.0, Combi Matrix) and spot intensity expressed
as median intensity.
Data analysis
Scanning data with similar median fluorescence intensity
were chosen for analysis. Fluorescence values of spots
with maximal intensity (signal saturation) at the chosenlaser intensity were extrapolated by linear regression,
using values gathered from the two next lower laser
intensities.
Gene filtering
Non-specific binding was determined from fluorescence
values of all non-specific probes. The cut-off for specific
binding was set as the upper 95% confidence interval of
the mean signal intensity of the non-specific probes. For
each comparison, probes were excluded when the mean
values for both strains to be compared were under the
determined cut-off. For comparisons involving in vitro
generated mutants derived from plasmid-free strains
RN4220 or ATCC6538, analysis was performed using
only probes sets gathered from the genomes of S. aureus
TW20 and Mu50.
Data transformation, normalization and analysis
The fluorescence values were log2 transformed. For each
set of comparison, stage-wise quantile normalization was
performed, using a script written in the statistical com-
puting environment of R (R Development Core Team,
2011), according to Deshmukh et al. [52]. Significantly
differentially regulated genes were determined by using
the Significance Analysis of Microarrays method (SAM,
Excel Add- in version 4.0) originally developed at Stan-
ford University lab [53]. For each comparison, the delta
value was set to obtain a conservative median false dis-
covery rate (FDR) of 1% and the fold change cut-off
value was set to 2. For investigating common up- or
down- regulated genes in the 4 triclosan resistant clinical
strains, the FDR value was set to 5%.
Quantitative real-time PCR
Reverse transcription of total RNA to single-stranded
cDNA was performed on selected laboratory strains and
clinical isolates using the High Capacity RNA-to-cDNA
Kit (Applied Biosystems). Quantitative real-time PCR
was carried out using SYBR® Green PCR Master Mix
(Applied Biosystems) and the reactions were performed in
triplicate, according to the manufacturer’s instructions, using
a 7500 Fast Real-time PCR System (Applied Biosystems).
The fabI gene was amplified using the primers 5′-GT
CCAATCCGTACATTAAGTGCA-3′ and 5′-TCACCTG
TAACGCCACTTGATAA-3′. The results were normal-
ised to the housekeeping gene gyrA amplified using the
primers 5′-ACGTCAACGTATTGTTGTCACTG-3′ and
5′-TTACGCACATCAATAACGACACG-3′. Transcription
levels were determined using the 2-ΔΔCT method [54].
Availability of supporting data
The data sets supporting the results of this article are
available in the ArrayExpress repository, (http://www.e-
bi.ac.uk/arrayexpress/) under accession numbers A-MEXP-
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array raw results).
Additional files
Additional file 1: Supplementary data S1: Relevant information of
S. aureus strains analysed.
Additional file 2: Supplementary data S2: Statistically significant
genes (up- or down-regulated). FabI-specific probes are highlighted in
yellow. In bold, the mean value of the fold increase/decrease. Gene are
presented in the decreasing fold change for the upregulated gene and
in increase fold change for the downregulated genes. The fold change
values of every single probe are also indicated. Probes are described as
follow: Probe ID/Probe sequence/Gene Name/NCBI Protein Reference Se-
quence number/Protein product name.
Additional file 3: Supplementary data S3: detailed informations on
the genes commonly up- or down-regulated in the 4 clinical
S. aureus characterized by a reduced susceptibility to triclosan.
Described are the gene locus and Uniprot ID as found for the TW20 or
MU50 genomes, as well as the associated KEGG orthology and gene
ontologies (GO) when available. GO terms were organized in 3
categories: “Biological Process”, “Molecular Function” and “Cellular
Component”.
Additional file 4: Supplementary data S4: list of genome sequences
and respective accession numbers used for probes design.
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